A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared
ASCO-GI 2023: Zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) with claudin-18.2+ (CLDN18.2+) / HER2− locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary results ...
New potential standard-of-care for patients with CLDN18.2+/HER2- LA unresectable or mG/GEJ adenocarcinoma – an international perspective
Zolbetuximab for CLDN18.2+ GEC - Slideset Download - ASCO GI 2023 | CCO
Gastric Cancer - Zolbetuximab Prolongs Survival - TRIAL-IN Pharma
Zolbetuximab bei Magenkrebs und Krebs des gastroösophagealen Übergangs – Arznei-News
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 ...
SPOTLIGHT: zolbetuximab plus chemotherapy prolongs PFS and OS in CLDN18.2+ metastatic gastric cancer | VJOncology
Astellas Pharma US on LinkedIn: Astellas to Present Positive Findings from Phase 3 SPOTLIGHT Trial of…
Zolbetuximab regimen extends survival in gastric, gastroesophageal junction cancer subset
Asco-GI 2023 – zolbetuximab sheds light on Claudin18.2 expression | Evaluate
ASCO-GI 2023: Zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) with claudin-18.2+ (CLDN18.2+) / HER2− locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary results ...
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 ...
ASCO-GI 2023: Zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) with claudin-18.2+ (CLDN18.2+) / HER2− locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary results ...
FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma - ScienceDirect
Zolbetuximab Meets Primary Endpoint in Phase 3 SPOTLIGHT Trial in Treatment in Gastric Cancers - Onco'Zine
Zolbetuximab benefits subset of patients with gastric, gastroesophageal junction cancer
FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma - ScienceDirect
Shelley Shaw on LinkedIn: Astellas Announces Zolbetuximab Meets Primary Endpoint in Phase 3…
Claudin18.2 Targeted Therapies In Cancer | Biopharma PEG
Zolbetuximab plus mFOLFOX6 successful in CLDN18.2-positive subgroup of gastric cancer - Medical Conferences
Astellas to Present Positive Findings from Phase 3 SPOTLIGHT Trial of Zolbetuximab during 2023 ASCO GI Cancers
Zolbetuximab With mFOLFOX6 Meets Primary Endpoint in SPOTLIGHT Trial
ASCO-GI 2023: Zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) with claudin-18.2+ (CLDN18.2+) / HER2− locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary results ...
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind ...
ASCO-GI 2023: Zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) with claudin-18.2+ (CLDN18.2+) / HER2− locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary results ...
